Differential expression of VEGF121, VEGF165 and VEGF189 in angiomas and squamous cell carcinoma cell lines of the head and neck

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 805-810

  Chengzhong, C A I ^a   Böttcher, Martina C ^a   Werner, Jochen A ^a   Mandic, Robert ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Head and neck; Hemangioma; HNSCC; Vascular malformation; VEGF splice variant

Indexed keywords

GROWTH FACTOR; ISOPROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CONGENITAL BLOOD VESSEL MALFORMATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HEMANGIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MUCOSA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TISSUE LEVEL; TONSIL; BIOSYNTHESIS; GENETICS; HEAD AND NECK TUMOR; METABOLISM; TUMOR CELL LINE; VASCULARIZATION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HEMANGIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951034048     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nagy JA, Dvorak AM and Dvorak HF: VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2: 251-275, 2007.
2. Ferrara N and vis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
3. Houck KA, Ferrara N, Winer J, Cachianes G, Li B and Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814, 1991.
4. 189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci USA 99: 6023-6028, 2002.
5. 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62: 4123-4131, 2002.
6. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM and Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79: 233-269, 1997.
7. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002.
8. Mentzel T, Brown LF, Dvorak HF, Kuhnen C, Stiller KJ, Katenkamp D and Fletcher CD: The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch 438: 13-22, 2001.
9. Molica S, Vacca A, Levato D, Merchionne F and Ribatti D: Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res 28: 321-324, 2004.
10. Yasui H, Hideshima T, Richardson PG and Anderson KC: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 132: 385-397, 2006.
11. Brown LF, Tognazzi K, Dvorak HF and Harrist TJ: Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148: 1065-1074, 1996.
12. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF and Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80: 1945-1953, 1997.
13. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF and Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87: 1237-1245, 1995.
14. Tong M, Lloyd B, Pei P and Mallery SR: Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. J Cell Biochem 105: 1202-1210, 2008.
15. Mandic R, Schamberger CJ, Muller JF, Geyer M, Zhu L, Carey TE, Grenman R, Dunne AA and Werner JA: Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 11: 6845-6852, 2005.
16. 111 is induced by genotoxic agents. J Cell Biol 179: 1261-1273, 2007.
17. Ng YS, Rohan R, Sunday ME, Demello DE and D'Amore PA: Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 220: 112-121, 2001.
18. 188. Nat Med 5: 495-502, 1999.
19. Bacic M, Edwards NA and Merrill MJ: Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 12: 11-15, 1995.
20. 165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Int J Cancer 120: 2096-2109, 2007.
21. 121 is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16-F10 melanoma growth. Acta Biochim Pol 56: 115-124, 2009.
22. Eivazi B, Ardelean M, Baumler W, Berlien HP, Cremer H, Elluru R, Koltai P, Olofsson J, Richter G, Schick B and Werner JA: Update on hemangiomas and vascular malformations of the head and neck. Eur Arch Otorhinolaryngol 266: 187-197, 2009.
23. Elias AP and Dias S: Microenvironment changes (in pH) affect VEGF alternative splicing. Cancer Microenviron 1: 131-139, 2008.
24. Grunstein J, Masbad JJ, Hickey R, Giordano F and Johnson RS: Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol 20: 7282-7291, 2000.
25. Nakamura M, Abe Y and Tokunaga T: Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int 52: 331-339, 2002.